Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

University of Victoria

$64,093.00

Antibody-nanoparticle conjugates as molecular imaging agents for solid brain tumour (glioma)

FY 2012-13

Summary
Glioblastoma multiforme (GBM) (WHO grade IV) is a highly aggressive tumour with distinct histopathological features including high proliferation, necrosis, and considerable neo-vascularization. GBM remains one of the most devastating cancers and is among the most common solid tumours in children. Radiographic and histological evidence have determined that increased tumour vascularity is correlated with the clinical grade of gliomas. At present, tissue samples are required for absolute classification, from which the outcome may be predicted and adjuvant therapies, such as radio and/or chemotherapy, may be determined. Therefore, there is an unmet clinical need to develop a non-invasive method to assess the degree of glioma vascularity and determine the associated clinical aggressiveness. Such a molecular imaging method could significantly improve the clinical management of gliomas. The application of molecular imaging to CNS neoplasms would ensure more accurate diagnosis if an appropriate targeted contrast agent were developed. Previously in our laboratory, the insulin-like growth factor-binding protein-7 (IGFBP7) has been discovered to be a highly up-regulated biomarker specific for GBM vessels and a single domain antibody (sdAbs) that target against IGFBP7 has been developed. Bioconjugation of sdAbs to magnetic resonance (MR) and near-infrared (NIR) imaging contrast agents is a novel method that has the potential to provide accurate molecular imaging of GBM vessels in the clinic. MRI is an advanced 3D non-invasive imaging modality, but the lack of molecular MR imaging contrast agents with sufficient specificity and high relaxivity, and thus MR contrast sensitivity, is a major impediment. We propose to make antibody-nanoparticle conjugates, more specifically to make MR molecular imaging agents consisting of anti-IGFBP7 sdAb targeted FeCo nanoparticles, which are predicted to have a 3 times stronger magnetic moment than 20 nm SPIO (superparamagnetic iron oxide) thus providing better targeted tissue contrast. In addition, it has a turn-on near-infrared optical probe.
Program
Collaborative Health Research Projects
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
398165-2011
Name nom
vanVeggel, Frank
Department département
Chemistry
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2011
Award amount
64093
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1100
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Health, education and social services
Area of application fr
Santé publique, éducation et services sociaux
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
2
Nb partie
3
Application title
Antibody-nanoparticle conjugates as molecular imaging agents for solid brain tumour (glioma)
Keyword
NSERC
Application summary
Glioblastoma multiforme (GBM) (WHO grade IV) is a highly aggressive tumour with distinct histopathological features including high proliferation, necrosis, and considerable neo-vascularization. GBM remains one of the most devastating cancers and is among the most common solid tumours in children. Radiographic and histological evidence have determined that increased tumour vascularity is correlated with the clinical grade of gliomas. At present, tissue samples are required for absolute classification, from which the outcome may be predicted and adjuvant therapies, such as radio and/or chemotherapy, may be determined. Therefore, there is an unmet clinical need to develop a non-invasive method to assess the degree of glioma vascularity and determine the associated clinical aggressiveness. Such a molecular imaging method could significantly improve the clinical management of gliomas. The application of molecular imaging to CNS neoplasms would ensure more accurate diagnosis if an appropriate targeted contrast agent were developed. Previously in our laboratory, the insulin-like growth factor-binding protein-7 (IGFBP7) has been discovered to be a highly up-regulated biomarker specific for GBM vessels and a single domain antibody (sdAbs) that target against IGFBP7 has been developed. Bioconjugation of sdAbs to magnetic resonance (MR) and near-infrared (NIR) imaging contrast agents is a novel method that has the potential to provide accurate molecular imaging of GBM vessels in the clinic. MRI is an advanced 3D non-invasive imaging modality, but the lack of molecular MR imaging contrast agents with sufficient specificity and high relaxivity, and thus MR contrast sensitivity, is a major impediment. We propose to make antibody-nanoparticle conjugates, more specifically to make MR molecular imaging agents consisting of anti-IGFBP7 sdAb targeted FeCo nanoparticles, which are predicted to have a 3 times stronger magnetic moment than 20 nm SPIO (superparamagnetic iron oxide) thus providing better targeted tissue contrast. In addition, it has a turn-on near-infrared optical probe.